F&P Healthcare lifts forecast, expands Mexico plant

Last updated 09:03 18/02/2014
FPH 7.150 -0.05 -0.69%
FPH

Click for a detailed chart

Relevant offers

Industries

MBIE warning for licensed building practitioners Molly Malone’s rent arrears claim in Wellington High Court Spark predicts Super Rugby final will smash data use record Two new housing areas in south Auckland to provide 1800 homes Pumpkin Patch gets new chief, warns of lower earnings BullionBuyer gold trader sentenced to prison Wellington-based Open Polytechnic to sell its online education platform iQualify Roam drives hard for success Kiwi leaders sleep rough for Big Sleepout Briscoe's Rod Duke: the man who would own Kathmandu

Fisher & Paykel Healthcare has raised its earnings guidance and brought forward plans to expand its manufacturing facility in Mexico.

The firm's annual profit for the year to March 31 is now seen at $97 million, up from the November forecast of $90-$95m.

"Demand during the second half has been very encouraging, particularly for our Simplus, Eson and Pilairo Q masks, which are used for the treatment of OSA,'' chief executive Michael Daniell said.

''Operating margin has continued to improve as a result of product mix, operating efficiency gains and manufacturing at our Mexico facility".

The company said it will expand its plant in Tijuana, Mexico, spending $4m on a fit-out to increase the manufacturing area by two thirds.

The plant is expected to be manufacturing approximately half of the company's consumable product volume within three years, F & P Healthcare said.

"We have brought forward the expansion of the Tijuana facility to ensure that we can meet anticipated demand as a result of strong customer acceptance of products such as our new masks and Optiflow oxygen therapy system,'' Daniell said.

In the United States later this year, Medicare will begin to penalise hospitals for excessive chronic respiratory patient readmissions, he said.

''We believe that this will increase the demand for our products which can help to improve care in the home for patients with chronic respiratory disease."

The company said it will continue to invest at its site in Auckland, where a number of new product platforms and associated manufacturing lines were being developed.

Ad Feedback

- Fairfax Media

Special offers

Featured Promotions

Sponsored Content